NASDAQ: SLDBSolid Biosciences Inc Stock
$8.77-0.34 (-3.73%)
Updated Apr 24, 2024
SLDB Price
$8.77
Fair Value Price
$2.40
Market Cap
$331.13M
52 Week Low
$1.81
52 Week High
$15.05
P/E
-1.82x
P/B
2.62x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$96.02M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.3
Operating Cash Flow
-$94M
Beta
1.08
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
SLDB Overview
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SLDB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SLDB ($8.77) is overvalued by 265.2% relative to our estimate of its Fair Value price of $2.40 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SLDB ($8.77) is not significantly undervalued (265.2%) relative to our estimate of its Fair Value price of $2.40 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SLDB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SLDB due diligence checks available for Premium users.
Be the first to know about important SLDB news, forecast changes, insider trades & much more!
SLDB News
Valuation
SLDB fair value
Fair Value of SLDB stock based on Discounted Cash Flow (DCF)
Price
$8.77
Fair Value
$2.40
Overvalued by
265.20%
SLDB ($8.77) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SLDB ($8.77) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SLDB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SLDB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.82x
Industry
15.69x
Market
41.27x
SLDB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.62x
Industry
5.86x
SLDB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SLDB's financial health
Profit margin
Revenue
$0.0
Net Income
-$20.3M
Profit Margin
0%
SLDB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$164.9M
Liabilities
$38.5M
Debt to equity
0.3
SLDB's short-term assets ($129.73M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SLDB's short-term assets ($129.73M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SLDB's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SLDB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$20.8M
Investing
$45.3M
Financing
$505.0k
SLDB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SLDB vs Biotech Stocks
Solid Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.